Dyno Therapeutics Partners with NVIDIA AI to Enhance Development of High-Performance Biological Sequences
Friday, May 10, 2024
Dyno Therapeutics has recently announced an exciting collaboration with NVIDIA aimed at leveraging Dyno's cutting-edge artificial intelligence (AI) and in vivo experimentation prowess alongside NVIDIA's BioNeMo AI-driven drug design platform. This partnership is poised to propel advancements in biological sequence design, a critical aspect of healthcare and technology innovation.
Over the past decade, Dyno has been at the forefront of AI-powered sequence design, pioneering breakthroughs in creating validated biologics using generative AI. Their recent successes include optimized capsid products facilitating enhanced in vivo delivery of genetic therapies, such as the Dyno eCap™ 1 and Dyno bCap™ 1 capsids. These achievements underscore the potential of sequence design to revolutionize healthcare outcomes.
Recognizing the pivotal role of computational resources in advancing sequence design capabilities, Dyno is teaming up with NVIDIA to harness their robust computing infrastructure and expertise. NVIDIA's cloud infrastructure, software, and BioNeMo framework will empower Dyno to accelerate research and deployment of advanced machine-learning models for sequence design.
The collaboration will see Dyno's machine learning experts collaborating closely with NVIDIA AI specialists to scale and optimize Dyno's AI-powered algorithms. By leveraging NVIDIA's resources, Dyno aims to navigate sequence space more efficiently, aligning with the rapid pace of modern computation and unlocking transformative medicines.
According to Eric Kelsic, Dyno's CEO, combining AI with high-throughput molecular experimentation represents a paradigm shift in bioengineering. This collaboration with NVIDIA will further enhance Dyno's capabilities, enabling the rapid development of medicines with profound impacts on patient care.
Rory Kelleher, NVIDIA's Global Head of Business Development for Life Sciences, emphasizes the potential of generative AI to revolutionize drug discovery and development. Through this collaboration, NVIDIA aims to accelerate high-performance biological sequence design, fostering innovation in healthcare.
Ultimately, the partnership between Dyno and NVIDIA holds promise for patients worldwide, offering the potential to create a myriad of new medicines through advanced sequence design technologies. By leveraging Dyno's expertise and NVIDIA's computational prowess, the collaboration seeks to accelerate the pace of therapeutic discovery and improve patient outcomes.
Source: businesswire.com
